comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists in Diseases: Mechanisms, Clinical Evidence, Emerging Therapies Kidney and Cardiovascular Outcomes Among

GIP(3-30)NH 2 demonstrated an inhibition of the GIP-potentiated glucose-stimulated insulin secretion by 82%

SeckTNauckMShengDSungaSDaviesMJSteinPPet al

Due to their cost, however, coverage of GLP-1s for obesity treatment in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, and GLP-1 coverage in Medicare for treatment of obesity is prohibited under current law

Patient-specific factors including age, comorbidities, and ability to implement lifestyle modifications significantly influence appropriate treatment duration

As in the previously mentioned study there was no difference between GLP-1 receptor agonists and SGLT2 inhibitors in reducing the risk of MACE, but when compared to DPP-4 inhibitors SGLT2 inhibitors significantly reduced cardiovascular and total death